Celcuity

Targeted therapies only work when inhibiting the target pathway disrupts the oncogenic process. Celcuity’s platform provides unparalleled insights into oncogenic pathways. We harness these insights to develop new targeted therapies for cancer patients. Our lead candidate is gedatolisib, a dual PI3K - mTOR inhibitor.